Michael P. Stehn
Corporate Officer/Principal at Parenteral Drug Association
Michael P. Stehn active positions
| Companies | Position | Start | End |
|---|---|---|---|
| Parenteral Drug Association | Corporate Officer/Principal | - | - |
Career history of Michael P. Stehn
Former positions of Michael P. Stehn
| Companies | Position | Start | End |
|---|---|---|---|
| AKORN, INC. | Chief Operating Officer | 31/12/1989 | 04/09/2012 |
| Corporate Officer/Principal | 04/09/2012 | 31/01/2020 | |
The Rugby Group, Inc.
 The Rugby Group, Inc. Pharmaceuticals: MajorHealth Technology Part of AbbVie, Inc., The Rugby Group, Inc. is a company that develops and manufactures generic drugs. The company is based in Parsippany, NJ. The Rugby Group was acquired by Actavis, Inc. from Hoechst AG on August 26, 1997 for $70 million. | Corporate Officer/Principal | - | - |
Training of Michael P. Stehn
| Fairleigh Dickinson University | Undergraduate Degree |
Statistics
International
| United States | 5 |
Operational
| Corporate Officer/Principal | 3 |
| Chief Operating Officer | 1 |
| Undergraduate Degree | 1 |
Sectoral
| Health Technology | 3 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 3 |
|---|---|
Akorn, Inc.
 Akorn, Inc. Pharmaceuticals: MajorHealth Technology Akorn, Inc. engages in the development, manufacture, and marketing of generic and prescription pharmaceuticals, and animal and consumer health products. It manufactures and markets branded and generic products including ophthalmic, injectable, oral liquids, topical, inhalants, and nasal sprays. The company was founded in 1971 and is headquartered in Lake Forest, IL. | Health Technology |
The Rugby Group, Inc.
The Rugby Group, Inc. Pharmaceuticals: MajorHealth Technology Part of AbbVie, Inc., The Rugby Group, Inc. is a company that develops and manufactures generic drugs. The company is based in Parsippany, NJ. The Rugby Group was acquired by Actavis, Inc. from Hoechst AG on August 26, 1997 for $70 million. | Health Technology |
| Parenteral Drug Association |
- Stock Market
- Insiders
- Michael P. Stehn
- Experience
